DPP4 and cancer: A meta-analysis of 72 randomized controlled clinical trials, however, encompassing 70,000 enrolled participants, did not substantiate significant associations between the use of DPP-4 inhibitors and cancer development in comparison with the use of other active drugs or placebo [64].